Reinerová M, Veselovská Z, Ausch C, Rosen H R
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovakia.
Neoplasma. 1996;43(6):363-6.
Placental isoferritin (PLF), an acidic isoform of ferritin, and its unique superheavy chain of 43 kDa (p43) has been described to be synthesized by human breast cancer cells. Physiologically, p43 PLF produced by the placenta is involved in immune suppression of maternal lymphocytes aimed at fetal antigens. A study was carried out to elucidate a paradigm of p43 occurrence in breast cancer patients. Immunosuppression of cytotoxic CD8+ lymphocytes was measured via inhibition of blast transformation in concanavalin A (ConA) stimulated peripheral blood lymphocytes (PBL) using 3H-thymidine uptake in vitro. PBLs were cultivated from 29 women having benign lesions in the breast as well as from 41 patients with breast adenocarcinoma. In breast cancer patients addition of p43 significantly inhibited the activation of lymphocytes proliferation by ConA compared to women with benign tumors. The addition of indomethacin or levamisole did not influence this inhibitory effect of p43 in breast cancer patients. Presence of interleukin-2 in cultures was able to overcome the inhibitory effect of p43 on CD8+ lymphocytes proliferation from women having breast adenocarcinomas and to increase its value in patients with benign lesions.
胎盘铁蛋白（PLF）是铁蛋白的一种酸性异构体，其独特的43 kDa超重链（p43）已被描述为由人乳腺癌细胞合成。在生理情况下，胎盘产生的p43 PLF参与针对胎儿抗原的母体淋巴细胞的免疫抑制。开展了一项研究以阐明乳腺癌患者中p43的出现模式。通过在体外使用3H-胸腺嘧啶核苷摄取来抑制伴刀豆球蛋白A（ConA）刺激的外周血淋巴细胞（PBL）中的母细胞转化，来测量细胞毒性CD8 +淋巴细胞的免疫抑制。从29名患有乳腺良性病变的女性以及41名乳腺腺癌患者中培养PBL。与患有良性肿瘤的女性相比，在乳腺癌患者中添加p43显著抑制了ConA对淋巴细胞增殖的激活。添加消炎痛或左旋咪唑并不影响p43对乳腺癌患者的这种抑制作用。培养物中白细胞介素-2的存在能够克服p43对乳腺腺癌女性CD8 +淋巴细胞增殖的抑制作用，并增加患有良性病变患者的该值。
